SEARCH:   Advanced

Blood, 15 February 2006, Vol. 107, No. 4, pp. 1505-1512. Prepublished online as a Blood First Edition Paper on October 25, 2005; DOI 10.1182/blood-2005-01-0258. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-01-0258v1 107/4/1505    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Filaci, G. Articles by Indiveri, F. Search for Related Content PubMed PubMed Citation Articles by Filaci, G. Articles by Indiveri, F. Related Collections Immunobiology Neoplasia Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer Gilberto Filaci, Marco Fravega, Maurizio Setti, Paolo Traverso, Enrico Millo, Daniela Fenoglio, Simone Negrini, Francesca Ferrera, Andrea Romagnoli, Monica Basso, Paola Contini, Marta Rizzi, Massimo Ghio, Umberto Benatti, Gianluca Damonte, Jean Louis Ravetti, Giorgio Carmignani, Maurizio Zanetti, and Francesco Indiveri From the Departments of Internal Medicine; Urology; Experimental Medicine, Biochemistry Section; and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Italy; Center of Advanced Biotechnology, Genoa, Italy; Institute Giannina Gaslini, Genoa, Italy; Department of Anatomic Pathology, San Martino Hospital-Genoa, Italy; and the Department of Medicine and Cancer Center, University of California at San Diego, La Jolla, CA. Telomerase is considered a universal tumor-associated antigen (TAA) due to its high rate of expression by cancers (90%), and clinical trials are in progress to test the immunotherapeutical efficacy of antitelomerase immunization in patients with cancer. However, the data concerning frequency and functional activity of telomerase-specific cytotoxic T lymphocytes (CTLs) in patients with cancer are few and conflicting, although their knowledge would be mandatory to predict the efficacy of telomerase-specific immunotherapy in selected patients. We performed this study to analyze frequency and cytolytic function of circulating CD8+ T lymphocytes specific for the p540 telomerase peptide in a series of human leukocyte antigen (HLA)–A2+ cancer patients. The results show that most patients with cancer have circulating telomerase-specific CD8+ T lymphocytes, but a high frequency of telomerase-specific CTLs are present only in a fraction of them. Furthermore, CTL lines able to kill telomerase-positive tumor cells, including autologous cancer cells, can be expanded ex vivo from some, but not all, patients with cancer. In conclusion, the results of the study support the development of clinical protocols using telomerase peptides as an immunizing agent. However, they underline the necessity to study single patients immunologically before undergoing vaccination, to select the patients adequately, and to eventually adapt the immunization schedule to the patient's immunologic status. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Mennuni, S. Ugel, F. Mori, B. Cipriani, M. Iezzi, T. Pannellini, D. Lazzaro, G. Ciliberto, N. La Monica, P. Zanovello, et al. Preventive Vaccination with Telomerase Controls Tumor Growth in Genetically Engineered and Carcinogen-Induced Mouse Models of Cancer Cancer Res., December 1, 2008; 68(23): 9865 - 9874. [Abstract] [Full Text] [PDF] I. Pellicciotta, X. Cortez-Gonzalez, R. Sasik, Y. Reiter, G. Hardiman, P. Langlade-Demoyen, and M. Zanetti Presentation of Telomerase Reverse Transcriptase, a Self-Tumor Antigen, is Down-regulated by Histone Deacetylase Inhibition Cancer Res., October 1, 2008; 68(19): 8085 - 8093. [Abstract] [Full Text] [PDF] S. M. Domchek, A. Recio, R. Mick, C. E. Clark, E. L. Carpenter, K. R. Fox, A. DeMichele, L. M. Schuchter, M. S. Leibowitz, M. H. Wexler, et al. Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance Cancer Res., November 1, 2007; 67(21): 10546 - 10555. [Abstract] [Full Text] [PDF] G. Filaci, D. Fenoglio, M. Fravega, G. Ansaldo, G. Borgonovo, P. Traverso, B. Villaggio, A. Ferrera, A. Kunkl, M. Rizzi, et al. CD8+CD28 T Regulatory Lymphocytes Inhibiting T Cell Proliferative and Cytotoxic Functions Infiltrate Human Cancers J. Immunol., October 1, 2007; 179(7): 4323 - 4334. [Abstract] [Full Text] [PDF] G. Parmiani, V. Russo, A. Marrari, G. Cutolo, C. Casati, L. Pilla, C. Maccalli, L. Rivoltini, and C. Castelli Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy Clin. Cancer Res., October 1, 2007; 13(19): 5675 - 5679. [Full Text] [PDF] M. A. Purbhoo, Y. Li, D. H. Sutton, J. E. Brewer, E. Gostick, G. Bossi, B. Laugel, R. Moysey, E. Baston, N. Liddy, et al. The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor Mol. Cancer Ther., July 1, 2007; 6(7): 2081 - 2091. [Abstract] [Full Text] [PDF] O. Adotevi, K. Mollier, C. Neuveut, S. Cardinaud, E. Boulanger, B. Mignen, W.-H. Fridman, M. Zanetti, P. Charneau, E. Tartour, et al. Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses. Clin. Cancer Res., May 15, 2006; 12(10): 3158 - 3167. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020